OvaScience to Present at Lazard Capital Markets 8th Annual Healthcare Conference
Michelle Dipp, CEO, to present at Lazard conference on Wednesday November 16th, 2011
BOSTON, Mass., Nov. 15, 2011 - OvaScience™, an innovative life science company dedicated to improving the treatment of infertility, today announced that the company has been invited to present at the Lazard Capital Markets 8th Annual Healthcare Conference, being held November 16-17 at The Pierre Hotel in New York City. Michelle Dipp, M.D., Ph.D., chief executive officer of OvaScience, will present an overview of the company at 10:30 a.m. on Wednesday, November 16.
OvaScience is an innovative life science company dedicated to improving the treatment of infertility. OvaScience’s first product, AUGMENT, aims to increase the success of in vitro fertilization (IVF). OvaScience’s patented technology, exclusively licensed from Harvard Medical School and Massachusetts General Hospital, allows a woman to use her own cellular energy to revitalize her egg. The company’s team of scientists, physicians and advisers are recognized leaders in the field of reproductive medicine. Privately-held, OvaScience was co-founded by Longwood Fund and Professors Jonathan Tilly, Ph.D., Massachusetts General Hospital and Harvard Medical School, and David Sinclair, Ph.D., Harvard Medical School. For more information, please visit the company’s website at www.ovascience.com.